Shuttle Pharma doses first three patients in Phase 2 trial of Ropidoxuridine for glioblastoma

Shuttle Pharmaceuticals Holdings, Inc.

First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma.
Trial targets IDH wild-type, methylation-negative glioblastoma patients with no cure.
Initial 40 patients randomized to 1,200 mg/day or 960 mg/day; then add 14 on optimal dose.
Expected trial completion in 18-24 months.
Orphan Drug Designation from FDA provides potential 7-year exclusivity if approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.